Parra L, Sartori B, Fernandes D, Fachin L, Nogueira M, Belone A
Immunogenetics. 2022; 75(2):81-89.
PMID: 36229691
DOI: 10.1007/s00251-022-01279-0.
Rohn H, Lang C, Schramm S, Heinemann F, Trilling M, Gackler A
J Immunol Res. 2022; 2022:4829227.
PMID: 35600048
PMC: 9119744.
DOI: 10.1155/2022/4829227.
Westin A, Gardinassi L, Soares E, da Silva J, Donadi E, Souza C
Arch Dermatol Res. 2021; 314(3):247-256.
PMID: 33811555
DOI: 10.1007/s00403-021-02218-x.
Pi L, Zhang Z, Gu Y, Wang X, Wang J, Xu J
PeerJ. 2020; 8:e8196.
PMID: 31938574
PMC: 6953351.
DOI: 10.7717/peerj.8196.
Sipak O, Ryl A, Grzywacz A, Laszczynska M, Zimny M, Karakiewicz B
Int J Environ Res Public Health. 2019; 16(9).
PMID: 31052398
PMC: 6539819.
DOI: 10.3390/ijerph16091546.
Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma.
Crocchiolo R, Ringden O, Bay J, Blaise D, Omasic B, Mazzi B
Bone Marrow Transplant. 2017; 53(2):213-218.
PMID: 29131154
DOI: 10.1038/bmt.2017.243.
Trogocytic intercellular membrane exchanges among hematological tumors.
LeMaoult J, Caumartin J, Daouya M, Switala M, Rebmann V, Arnulf B
J Hematol Oncol. 2015; 8:24.
PMID: 25887663
PMC: 4371622.
DOI: 10.1186/s13045-015-0114-8.
Synthetic HLA-G proteins for therapeutic use in transplantation.
LeMaoult J, Daouya M, Wu J, Loustau M, Horuzsko A, Carosella E
FASEB J. 2013; 27(9):3643-51.
PMID: 23752205
PMC: 3752534.
DOI: 10.1096/fj.13-228247.
Case-control study of HLA-G promoter methylation status, HPV infection and cervical neoplasia in Curitiba, Brazil: a pilot analysis.
Gillio-Tos A, da Graca Bicalho M, Fiano V, Grasso C, Tarallo V, De Marco L
BMC Cancer. 2012; 12:618.
PMID: 23265140
PMC: 3545901.
DOI: 10.1186/1471-2407-12-618.
Shedding light on melanocyte pathobiology in vivo.
Zaidi M, De Fabo E, Noonan F, Merlino G
Cancer Res. 2012; 72(7):1591-5.
PMID: 22422936
PMC: 3319844.
DOI: 10.1158/0008-5472.CAN-11-2586.
HLA-G regulators in cancer medicine: an outline of key requirements.
Zidi I, Ben Amor N
Tumour Biol. 2011; 32(6):1071-86.
PMID: 21792710
DOI: 10.1007/s13277-011-0213-2.
Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer.
Allard M, Oger R, Vignard V, Percier J, Fregni G, Perier A
PLoS One. 2011; 6(6):e21118.
PMID: 21712991
PMC: 3119680.
DOI: 10.1371/journal.pone.0021118.
Interferon-γ links ultraviolet radiation to melanomagenesis in mice.
Zaidi M, Davis S, Noonan F, Graff-Cherry C, Hawley T, Walker R
Nature. 2011; 469(7331):548-53.
PMID: 21248750
PMC: 3140101.
DOI: 10.1038/nature09666.
Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association.
Donadi E, Castelli E, Arnaiz-Villena A, Roger M, Rey D, Moreau P
Cell Mol Life Sci. 2010; 68(3):369-95.
PMID: 21107637
PMC: 3021195.
DOI: 10.1007/s00018-010-0580-7.
Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?.
Amiot L, Ferrone S, Grosse-Wilde H, Seliger B
Cell Mol Life Sci. 2010; 68(3):417-31.
PMID: 21063893
PMC: 3426238.
DOI: 10.1007/s00018-010-0583-4.
Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV).
Guimaraes M, Soares C, Donadi E, Derchain S, Andrade L, Silva T
J Histochem Cytochem. 2009; 58(5):405-11.
PMID: 19786613
PMC: 2857812.
DOI: 10.1369/jhc.2009.954131.